English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Translation termination depends on the sequential ribosomal entry of eRF1 and eRF3.

MPS-Authors
/persons/resource/persons206931

Karki,  P.
Department of Physical Biochemistry, MPI for Biophysical Chemistry, Max Planck Society;

Locator
There are no locators available
Fulltext (public)

3138822.pdf
(Publisher version), 4MB

Supplementary Material (public)

3138822_Suppl.pdf
(Supplementary material), 371KB

Citation

Beissel, C., Neumann, B., Uhse, S., Hampe, I., Karki, P., & Krebber, H. (2019). Translation termination depends on the sequential ribosomal entry of eRF1 and eRF3. Nucleic Acids Research, 47(9), 4798-4813. doi:10.1093/nar/gkz177.


Cite as: http://hdl.handle.net/21.11116/0000-0004-49CE-3
Abstract
Translation termination requires eRF1 and eRF3 for polypeptide-and tRNA-release on stop codons. Additionally, Dbp5/DDX19 and Rli1/ABCE1 are required; however, their function in this process is currently unknown. Using a combination of in vivo and in vitro experiments, we show that they regulate a stepwise assembly of the termination complex. Rli1 and eRF3-GDP associate with the ribosome first. Subsequently, Dbp5-ATP delivers eRF1 to the stop codon and in this way prevents a premature access of eRF3. Dbp5 dissociates upon placing eRF1 through ATP-hydrolysis. This in turn enables eRF1 to contact eRF3, as the binding of Dbp5 and eRF3 to eRF1 is mutually exclusive. Defects in the Dbp5-guided eRF1 delivery lead to premature contact and premature dissociation of eRF1 and eRF3 from the ribosome and to subsequent stop codon readthrough. Thus, the stepwise Dbp5-controlled termination complex assembly is essential for regular translation termination events. Our data furthermore suggest a possible role of Dbp5/DDX19 in alternative translation termination events, such as during stress response or in developmental processes, which classifies the helicase as a potential drug target for nonsense suppression therapy to treat cancer and neurodegenerative diseases.